Cullinan Oncology, Inc. — Form 8-K Summary
Business Context and Reporting Period
The filing was submitted by Cullinan Oncology, Inc. (now identified in the request metadata as Cullinan Therapeutics, Inc.) under Item 5.02 of Form 8-K. The report date was December 27, 2021, with the filing signed December 29, 2021. The company’s common stock traded on the Nasdaq Global Select Market under the symbol CGEM.
Material Event
Morana Jovan-Embiricos notified the board of directors on December 27, 2021, that she intended to resign as a director effective December 31, 2021. She stated that the resignation was to dedicate more time to her role as Managing Partner of F2 Ventures Ltd. and its pre-public portfolio companies.
The company reported that the resignation did not result from any disagreement with the company regarding its operations, policies, or practices.
Financial Metrics and Outlook
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial performance data.
Risks, Contingencies, and Unusual Items
The principal disclosed event is the departure of a board member. The filing does not identify a replacement director, any change in committee assignments, or any related compensation arrangement.
Key Facts to Verify
- Confirm that Morana Jovan-Embiricos’s resignation became effective December 31, 2021.
- Verify whether the board appointed a replacement director or changed committee composition in a subsequent filing.
- Review later filings for any governance, strategic, or market disclosures related to the director transition.